Healthcare Industry News: ZOLL Medical
News Release - February 27, 2007
Exeter Hospital First Hospital in New Hampshire to Deploy Zoll AutoPulseCHELMSFORD, Mass.--(HSMN NewsFeed)--ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today reported that Exeter Hospital has deployed the ZOLL AutoPulse® Non-invasive Cardiac Support Pump. Exeter is the first hospital in New Hampshire to deploy the device, which automates the performance of CPR chest compressions.
Exeter Hospital Emergency Medical Services recently began utilizing the AutoPulse resuscitation device. The devices are deployed on Exeter Hospital Paramedic intercept vehicles, which serve 15 communities in the Exeter area.
"The AutoPulse, which automates the delivery of continuous CPR chest compressions, can give a patient a greater chance of survival," said Paul Luizzi, Director of EMS Services at Exeter Hospital. "It can keep doing CPR compressions without stopping, and can consistently circulate more blood than is possible with human hands. This technology can help our paramedics improve the quality of CPR performance, while allowing them to focus on other life-saving tasks."
About the AutoPulse
The major emphasis of the most recent American Heart Association Guidelines is on performing effective, high-quality CPR. The 2005 Guidelines recommend 30 compressions for every two rescue breaths--an increase from 15 compressions for every two breaths in the 2000 Guidelines. Furthermore, the Guidelines note that interrupting chest compressions can decrease the rate of survival from cardiac arrest.*
The AutoPulse is an automated, portable device with a load-distributing LifeBand® that squeezes the entire chest in a consistent, uninterrupted "hands-free"manner, delivering maximum blood flow to the heart and brain.* Additionally, it offers the benefit of freeing up rescuers to focus on other life-saving interventions.
About ZOLL Medical Corporation
ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation (with ZOLL's See-Thru CPR(TM) and Real CPR Help(TM) technologies), ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.
ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia.
Certain statements contained in this press release regarding matters that are not historical facts are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, ZOLL's ability to compete in the resuscitation business; acceptance of its recently launched products; changes in regulations affecting the healthcare industry; global economic conditions; and those other factors discussed in the section entitled "Risk Factors" in ZOLL's Quarterly Report on Form 10-Q, which was filed with the SEC on February 9, 2007.
©2007 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. Real CPR Help and See-Thru CPR are trademarks of ZOLL Medical Corporation. AutoPulse, LifeBand, and ZOLL are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.
*Clinical data available upon request.
Source: ZOLL Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.